Buprenorphine/naloxone - Orexo
Alternative Names: Naloxone/buprenorphine - Orexo; OX-219; PKX-219; ZubsolvLatest Information Update: 27 Jul 2023
Price :
$50 *
At a glance
- Originator PharmaKodex
- Developer Orexo
- Class Antidotes; Benzofurans; Cyclopropanes; Drug withdrawal therapies; Isoquinolines; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists; Opioid mu receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Opioid-related disorders
Most Recent Events
- 24 Jul 2023 Sun Pharmaceutical Industries appealed the patent litigation decision issued by the US District Court for the District of New Jersey relating to Orexo's patents protecting ZUBSOLV® in the US
- 01 Jul 2023 Orexo wins patent litigation against Sun Pharmaceuticals regarding buprenorphine/naloxone (ZUBSOLV®)submission in USA
- 30 Dec 2020 Orexohas patent protection for buprenorphine/naloxone in the US